drugset
drugset / Trial / NCT00030498

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

NCT00030498 ↗

Phase 1 Completed 75 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

Timeline

Start
2001-12
Primary completion
2007-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule — Oral

Indications

adenoid cystic carcinoma adult anaplastic ependymoma adult brainstem mixed glioma adult glioblastoma adult hepatocellular carcinoma adult oligodendroglioma anal carcinoma anaplastic astrocytoma anaplastic oligodendroglioma carcinoma of lip cervical carcinoma diffuse astrocytoma ependymoblastoma esophageal cancer esthesioneuroblastoma exocrine pancreatic carcinoma female breast carcinoma giant cell glioblastoma gliosarcoma hypopharynx squamous cell carcinoma inverted papilloma larynx verrucous carcinoma male breast carcinoma malignant mesothelioma metastatic squamous cell carcinoma myxopapillary ependymoma nasal cavity and paranasal sinus lethal midline granuloma nasal cavity and paranasal sinus squamous cell carcinoma nasopharyngeal carcinoma nasopharyngeal squamous cell carcinoma non-small cell lung carcinoma oral cavity mucoepidermoid carcinoma oropharynx squamous cell carcinoma ovarian carcinoma pilocytic astrocytoma prostate carcinoma salivary gland cancer subependymoma urinary bladder carcinoma verrucous carcinoma of oral cavity